OncoTherapy Science of Japan Plans Trials Soon On Biotech Cancer Vaccine (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japan's OncoTherapy Science expects to begin clinical trials this spring on a new type of cancer vaccine that relies on injecting protein fragments. The biotech technique involves genetically coded proteins injected into patients to stimulate their immune systems to attack cancers. The company has identified 16 cancer-related genes and has synthesized protein fragments and made vaccines for all of them, including ones aimed at the bladder, esophagus and lungs. (Click here for more - may require a subscription
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.